Recent clinical trials show that GLP-1 weight loss medications like Zepbound are more effective for women than men, prompting researchers to explore the biological and societal reasons behind this phenomenon.
In a surprising move, Novo Nordisk CEO Lars Fruergaard Jorgensen steps down as the company faces significant market challenges and competition from Eli Lilly's Zepbound. With share prices plummeting, the board seeks new leadership to navigate the turbulent landscape.
Eli Lilly introduces discounted higher doses of the weight loss drug Zepbound in a move to make the treatment more accessible to uninsured patients and address the growing demand for obesity treatments.
